No abstract available.
Carcinoma, Renal Cell*

No abstract available.
Neck* ; Urinary Bladder* ; Urinary Incontinence*

No abstract available.
Bacillus* ; Humans ; Urinary Bladder Neoplasms* ; Urinary Bladder*

No abstract available.
Uterus*

PURPOSE: We evaluated the effects of amitriptyline in patients with urinary frequency or pelvic pain syndrome and compared with propiverine hydrochloride (BUP-4(R)) and diazepam (Valium(R)). MATERIALS AND METHODS: One-hundred and sixty-eight patients with urinary frequency or pain were included and 38 out of 168 patients were lost to follow up. The patients with interstitial cystitis, UTI and neurogenic bladder were excluded. Amitriptyline group were instructed to take 25mg to 75mg of amitriptyline before bed. Propiverine hy drochloride and diazepam group were instructed to take 20mg, 4-6mg before bed, respectively. The clinical effects and side effects were evaluated after 4 weeks of medication. RESULTS: In the amitriptyline group, 73.1% in 78 patients with frequency, 68.3% in 60 pain, 65.6% in 32 nocturia, 53.8% in 26 weak urinary stream, 53.8% in 13 dysuria, 72.7% in 11 urgency showed symptom improvement. Urinary frequency and pain score were significantly decreased in the amitriptyline group. In the propiverine hydrochloride group, 66.7% in 21 patients with frequency, 38.8% in 18 pain showed symptom improvement. In the diazepam group, 37.5% in 24 patients with frequency, 31.3% in 16 pain showed symptom improvement. Side effects of amitriptyline had appeared in 24 (27.6%) out of 87 patients; 17 cases of dry mouth, 10 drowsiness, 2 agitation, 2 nausea, 1 constipation and 1 skin rash. CONCLUSIONS: Amitriptyline is useful in vague voiding symptoms especially in urinary frequency and chronic pelvic pain syndrome. It is equally effective in both men and women. Side effects are minimal and tolerable. A double-blind placebo-controlled trial is necessary for general acceptance in the future.
Amitriptyline* ; Constipation ; Cystitis, Interstitial ; Diazepam ; Dihydroergotamine ; Dysuria ; Exanthema ; Female ; Humans ; Lost to Follow-Up ; Male ; Mouth ; Nausea ; Nocturia ; Pelvic Pain* ; Rivers ; Sleep Stages ; Urinary Bladder, Neurogenic

No abstract available.
Humans ; Prednisolone* ; Prostate* ; Prostatic Neoplasms*

PURPOSE: Visual internal urethrotomy is a standard therapy for incomplete urethral stricture, and may also be a reasonable initial treatment for a short complete urethral stricture. The success rate and final results of the repeated internal urethrotomy were retrospectively assessed to figure out the appropriate indication for visual internal urethrotomy as an initial treatment for incomplete pendulous and bulbous urethral stricture; according to the stricture free month. MATERIALS AND METHODS: Between January 1990 and December 1999, an internal urethrotomy was primarily performed on 166 patients with urethral strictures. The exclusion criteria were complete urethral and posterior urethral stricture. Retrograde urethrography was performed under fluoroscopic control. When the stricture recurred, the urethrotomy was repeated as the primary procedure. RESULTS: With regard to the time to recurrence, the success rate of the group of stricture recurrence at 6 months was significantly lower than that of the stricture free group at 6 months. CONCLUSIONS: With regard to the stricture site and length, the stricture free month might be considered as an important predictor of the outcome of a repeated internal urethrotomy, and visual internal urethrotomy might be considered as an initial treatment method for incomplete urethral stricture under the following conditions; a bulbous stricture, a stricture length under 20mm, and stricture free at 6 months.
Constriction, Pathologic ; Endoscopy ; Humans ; Recurrence ; Reoperation ; Retrospective Studies ; Urethral Stricture*

We have performed percutaneous extraction of renal and upper ureter stones in 54 cases with use of the Storz percutaneous universal nephroscope(26Fr). With the patient under general anesthesia, a percutaneous tract was dilated up to 24Fr and the stone was immediately removed at one session. A variety of grasping and fragmentation techniques under fluoroscopic and endoscopic control were used to extract stones. Overall success rate was 65%. With increasing proficiency from accumulation of experience, rate of stone extraction has been increasing from 40% early in the series to 83% in the most recent cases. The advantage of this technique is that only 1 to 2cm skin incision is required to remove the stone with minimal postoperative morbidity, rapid convalescence, and sooner return to work. We conclude that percutaneous nephrolithotripsy appears to be an appropriate alternative to an open operation in most patients with symptomatic urolithiasis.
Anesthesia, General ; Convalescence ; Hand Strength ; Humans ; Return to Work ; Skin ; Ureter ; Urinary Calculi ; Urolithiasis

Patients with advanced urothelial tumors that relapse or persist following conventional therapy have poor prognosis. Management of the patients with recurrent local or disseminated urothelial tumors presents a difficult clinical problems. In 1985 Sternberg et al reported 71% of significant tumor regression and 50% of complete clinical remission with M-VAC (methotrexate, vinblastine, doxorubicin and Cisplatin) combination chemotherapy for treatment of advanced urothelial transitional cell carcinomas. Herein, we have experienced 13 cases of M-VAC combination chemotherapy in advanced urothelial tumors. Complete and partial remission was in achieved 46.2 per cent of the patients clinically, while 15.4 percent had a minor response and 38.4 per cent had progression with median survivals of 11.5, 8.5 and 7.4 months. Toxicity was significant. 15.4 per cent of the patients having experienced nadir sepsis, 30.8 per cent mucositis and 7.6 per cent cardiac toxicity. Median cycle length varied from 31.6 to 41.7 days for the first and 5th cycle respectively. This regimen has been efficacious in selected patients with advanced urothelial tumors.
Carcinoma, Transitional Cell ; Doxorubicin* ; Drug Therapy, Combination ; Humans ; Mucositis ; Prognosis ; Recurrence ; Sepsis ; Vinblastine*

PURPOSE: We evaluated the efficacy of the selective alpha1a and alpha1d antagonist (tamsulosin 0.2 mg) once daily in the treatment of patient with lower urinary tract symptom(LUTS), especially irritative symptom. MATERIALS AND METHODS: A total of 170 men with LUTS were treated for 12 weeks with tamsulosin 0.2 mg/day. The primary efficacy parameters are improvements in total, irritative and obstructive International Prostate Symptom Scores(IPSS), quality of life index(QOL index) and peak urinary flow rate(Qmax). Secondary efficacy parameters include percentage of patients with improvement in total, irritative and obstructive IPSS of at least 25%, Qmax of at least 30% and 3 ml/s increase in Qmax. RESULTS: Statistically significant improvements in all efficacy parameters were observed. Tamsulosin produced improvements in Qmax(21.7%), decrease in total, irritative, obstructive symptom score(25%, 19.1%, 29.2%) and QOL index(0.7 points). Seventy two patients(42.4%) had a > or =25% decrease in total symptom score, 71 patients (41.8%) in irritative and 90 patients(52.9%) in obstructive symptom score after 12 weeks(P<0.05). Sixty patients (35.3%) had a > or =30% increase and 67 patients(39.4%) had > or =3 ml/s increase in Qmax. CONCLUSIONS: This study showed beneficial short term results for the efficacy of selective alpha(1a) and alpha(1d) blocker (tamsulosin) in treating patients with LUTS, especially irritative symptom.
Humans ; Male ; Prostate ; Quality of Life ; Urinary Tract*